Cargando…
Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer
In the scenario of systemic treatment for advanced non-small cell lung cancer (NSCLC) patients, one of the most relevant breakthroughs is represented by targeted therapies. Throughout the last years, inhibitors of the epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), c-Ros o...
Autores principales: | Rebuzzi, Sara Elena, Zullo, Lodovica, Rossi, Giovanni, Grassi, Massimiliano, Murianni, Veronica, Tagliamento, Marco, Prelaj, Arsela, Coco, Simona, Longo, Luca, Dal Bello, Maria Giovanna, Alama, Angela, Dellepiane, Chiara, Bennicelli, Elisa, Malapelle, Umberto, Genova, Carlo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7961376/ https://www.ncbi.nlm.nih.gov/pubmed/33807876 http://dx.doi.org/10.3390/ijms22052625 |
Ejemplares similares
-
A Circulating Risk Score, Based on Combined Expression of Exo-miR-130a-3p and Fibrinopeptide A, as Predictive Biomarker of Relapse in Resectable Non-Small Cell Lung Cancer Patients
por: Marconi, Silvia, et al.
Publicado: (2022) -
Precision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable Patient
por: Rossi, Giovanni, et al.
Publicado: (2020) -
Prognostic Role of Soluble and Extracellular Vesicle-Associated PD-L1, B7-H3 and B7-H4 in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors
por: Genova, Carlo, et al.
Publicado: (2023) -
Prognostic Relevance of Circulating Tumor Cells and Circulating Cell-Free DNA Association in Metastatic Non-Small Cell Lung Cancer Treated with Nivolumab
por: Alama, Angela, et al.
Publicado: (2019) -
Correlation between B7-H4 and Survival of Non-Small-Cell Lung Cancer Patients Treated with Nivolumab
por: Genova, Carlo, et al.
Publicado: (2019)